Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271256 | 0.81 | KDM4E (0.34) | LMNAKDM4EAKR1B1PTGS2PSEN1 | |
| SCHEMBL272372 | 0.79 | P2RX7 (0.39) | PKMLMNAKDM4EAGTR1PTGS2 | |
| SCHEMBL270487 | 0.77 | PSEN1 (0.35) | KDM4EAKR1B1PSEN1PSEN2APH1B | |
| SCHEMBL16914843 | 0.74 | KDM4E (0.54) | LMNAKDM4EAKR1B1NPC1TAAR1 | |
| SCHEMBL31568330 | 0.74 | KDM4E (0.54) | LMNAKDM4EAKR1B1NPC1TAAR1 | |
| SCHEMBL1500897 | 0.72 | TAAR1 (0.41) | PKMLMNAKDM4EAKR1B1CES1 | |
| SCHEMBL271847 | 0.71 | PSEN1 (0.32) | LMNAKDM4EPSEN1PSEN2APH1B | |
| SCHEMBL139634 | 0.71 | PTGS1 (0.46) | LMNAPTGS2PTGS1MEN1MAPT | |
| SCHEMBL271826 | 0.71 | POLB (0.39) | PKMLMNAKDM4EPTGS2PTGS1 | |
| SCHEMBL20335484 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283373-B2 | Inhibitors of cytosolic phospholipase A2 | PFIZER INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102040550-B | Inhibitors of cytosolic phospholipase A2 | WYETH CORP | 2012-10-03 | — | — | CN | disclosed |
| CN-102040550-A | Inhibitors of cytosolic phospholipase A2 | WYETH CORP | 2011-05-04 | — | — | CN | disclosed |
| CN-101184729-B | Cytosolic phospholipase A2Inhibitors | WYETH CORP | 2011-02-16 | — | — | CN | disclosed |
| EP-1891006-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2248801-A1 | Inhibitors of cytosolic phospholipase a2 | Wyeth LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | WYETH LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-7557135-B2 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| CN-101184729-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2008-05-21 | — | — | CN | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | PKM 2659/4885LMNA 782/4885KDM4E 3787/4885 |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | PKM 2659/4885LMNA 782/4885KDM4E 3787/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | PKM 2659/4885LMNA 782/4885KDM4E 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.